{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_5",
        "affectedSection": "Schedules of Activities and Section 6",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of C-SSRS across all ongoing subjects and multiple study phases."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_5",
        "affectedSection": "Secondary Objectives",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removal of specific patient-reported outcome (PRO) endpoints."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_5",
        "affectedSection": "Sections 1, 2, 5, 6, 7, and Appendix 3",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Administrative changes and clarifications regarding dosing, PK sampling, and washout periods."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_4",
        "affectedSection": "Schedule of Activities, Sections 4, 6, and 7",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of Hepatitis B monitoring risk protocols for Taiwan."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_3",
        "affectedSection": "Screening and Treatment Periods (China Only)",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Inclusion of reflex HBV DNA testing and longitudinal monitoring for specific serology profiles."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_5",
        "reasonText": "To align with new cross-program processes for suicide severity rating.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_5",
        "reasonText": "To align secondary objectives with the Statistical Analysis Plan.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "High prevalence of specific Hepatitis B serology in Taiwan, requiring risk monitoring similar to China.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_3",
        "reasonText": "Requested by an Ethics Committee in China for study B7451013.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6",
        "afterText": "The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including the EOT/ET and/or the EOS visit.",
        "summary": "Added C-SSRS administration across multiple study visits."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_5",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Secondary Objectives",
        "beforeText": "EQ-5D-5L/EQ-5D-Y, FACIT-F/Peds-FACIT-F, and SF-36, acute patient-reported outcome (PRO) endpoints",
        "summary": "Removed specific PRO endpoints to align with the SAP."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_5",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5",
        "beforeText": "Administration of open-label Rescue treatment",
        "afterText": "Administration of the first dose of open-label Rescue treatment at the start of flare",
        "summary": "Clarified timing of first rescue treatment dose."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "7",
        "beforeText": "PK sample time point for analysis of PF-04965842",
        "afterText": "Additional blood collection at the current PK sample time point for analysis of PF-04965842 metabolites",
        "summary": "Added metabolite analysis to existing PK collection points."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Screening",
        "beforeText": "Subjects with HBsAg negative, HBcAb positive, and HBsAb positive serology",
        "afterText": "Subjects with HBsAg negative, HBcAb positive, and HBsAb positive serology will have reflex testing for HBV DNA. Subjects above LLQ will be excluded.",
        "summary": "Added mandatory reflex HBV DNA testing and exclusion criteria for China-based subjects."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}